Lupin 2024

CHPA comments on benefits of O-T-C switch for naloxone

CHPA comments on benefits of O-T-C switch for naloxone

CHPA comments on benefits of O-T-C switch for naloxone

WASHINGTON — The Consumer Healthcare Products Association (CHPA) released the following statement in advance of FDA Advisory Committee meetings considering OTC access to naloxone: “Over-the-counter (O-T-C) availability of naloxone – a life-saving emergency therapy for opioid overdoses that is currently only available with a prescription (Rx) – would be a critical step forward in public

Centrum 7/6  banner